Bittium Corporation’s Share Buy-Back Program Has Ended

Bittium Corporation
Other information disclosed according to the rules of the Exchange

Bittium Corporation’s Share Buy-Back Program Has Ended

Bittium Corporation, Stock Exchange Release, October 4, 2023, at 9:00 am (CEST+1)

The Board of Directors of Bittium Corporation (“Bittium” or the “Company”) decided on May 17, 2023, to launch a share buy-back program concerning Bittium’s own shares based on the authorization to repurchase own shares granted by the Annual General Meeting held on April 12, 2023.

Bittium has now completed the share buy-back program. The repurchases of the own shares began on May 19, 2023, and ended on October 3, 2023. During that period, Bittium repurchased 240,000 of its own shares for the total value of EUR 980,112.00 and an average price per share EUR 4.0838. The shares were acquired at the market price quoted at the time of acquisition in trading organized by Nasdaq Helsinki Ltd on a regulated market.

The shares acquired through the buy-back program are intended to be used for meeting obligations arising from share-based rewards to the Company’s management under the Company’s current and possible future incentive arrangements.

Bittium currently has 35,702,264 shares and holds 216,146 treasury shares, which corresponds to around 0.61 per cent of all the shares in the Company.

In Oulu, Finland, October 4, 2023

Bittium Corporation
The Board of Directors

Further information

Kari Jokela
CLO
Tel. +358 40 344 5258
 

Distribution

Nasdaq Helsinki Oy
Main media

Bittium

Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its over 35-year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. Bittium also provides healthcare technology products and services for biosignal measuring in the areas of cardiology and neurophysiology. Net sales in 2022 were EUR 82.5 million and operating profit was EUR 0.3 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com